CHICAGO, April 23, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeAllscripts Healthcare Solutions (Nasdaq: MDRX), Apple Inc. (Nasdaq: AAPL), Cerner Corp. (Nasdaq: CERN), Quality Systems (Nasdaq: QSII) and Athenahealth (Nasdaq: ATHN).
Allscripts Healthcare Solutions (Nasdaq: MDRX), a leading player in the health care information technology ("HCIT") market, reported the launch of Allscripts Wand. It provides clients of Allscripts Electronic Health/Medical Record ("EHR"/"EMR") an iPad application for frequently used features of Allscripts Enterprise and Professional offerings.
The utilization of Apple Inc.'s (Nasdaq: AAPL) iPad in healthcare is growing. It is reported that a significant proportion of physicians own an iPad or compatible device, which is higher than the general population.
The Wand holds intuitive appeal and permits comfortable usage with little assistance. Two benefits from its utilization are rapid access to data and efficient workflow. According to the company, the Allscripts Wand is intended to provide quick access to commonly used features of EHR.
The health care information technology market is competitive and price sensitive. Among others, Allscripts faces strong competition from Cerner Corp. (Nasdaq: CERN), Quality Systems (Nasdaq: QSII) and Athenahealth (Nasdaq: ATHN).
However, optimism about the growth prospects of select HCIT service providers remains high under the Obama Administration, which passed the Stimulus package in May 2009, aimed at increasing the use of electronic health record systems by medical practitioners.
The company has widened its user base after its mergers with Misys and Eclipsys and increased cross-selling opportunities. We believe that Allscripts is well positioned in the fast growing business of selling EHR/EMR to physician practices as well as inpatient settings.
The acquisition of Eclipsys provides the company with an acute care product for sale in concert with its ambulatory services. We opine that acute and ambulatory care will continue to converge in future and that Allscripts is well positioned to provide integrated clinical applications that will permit health care providers to satisfy HITECH Act requirements and eventually comply with an outcomes-based reimbursement system.
Strong bookings currently taking place, with both ambulatory and acute products doing well, may indicate that the Eclipsys products are popular in the market and that cross-selling synergies are for real.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.